MCID: SCH015
MIFTS: 71

Schizophrenia

Categories: Genetic diseases, Mental diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Schizophrenia

MalaCards integrated aliases for Schizophrenia:

Name: Schizophrenia 53 37 12 72 24 71 36 28 13 51 40 41 14 69
Schizophrenia with or Without an Affective Disorder 53 71
Schizophrenia, Susceptibility to 53 13
Schizophrenia 12 53 69
Sczd 53 71
Dementia Praecox 24
Schizophrenia 1 69
Schizophrenia-1 12

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant

Miscellaneous:
genetic heterogeneity
onset often in late adolescence
symptoms must occur for 6 months including 1 month of characteristic symptoms (e.g. delusions) to make diagnosis
multiple gene loci involved in causation of schizophrenia


HPO:

31
schizophrenia:
Inheritance heterogeneous autosomal dominant inheritance


Classifications:



External Ids:

OMIM 53 181500
Disease Ontology 12 DOID:5419
ICD9CM 34 295.8 295.80
MeSH 41 D012559
KEGG 36 H01649
ICD10 32 F20 F20.9

Summaries for Schizophrenia

MedlinePlus : 40 Schizophrenia is a serious brain illness. People who have it may hear voices that aren't there. They may think other people are trying to hurt them. Sometimes they don't make sense when they talk. The disorder makes it hard for them to keep a job or take care of themselves. Symptoms of schizophrenia usually start between ages 16 and 30. Men often develop symptoms at a younger age than women. People usually do not get schizophrenia after age 45. There are three types of symptoms: Psychotic symptoms distort a person's thinking. These include hallucinations (hearing or seeing things that are not there), delusions (beliefs that are not true), trouble organizing thoughts, and strange movements. "Negative" symptoms make it difficult to show emotions and to function normally. A person may seem depressed and withdrawn. Cognitive symptoms affect the thought process. These include trouble using information, making decisions, and paying attention. No one is sure what causes schizophrenia. Your genes, environment, and brain chemistry may play a role. There is no cure. Medicine can help control many of the symptoms. You may need to try different medicines to see which works best. You should stay on your medicine for as long as your doctor recommends. Additional treatments can help you deal with your illness from day to day. These include therapy, family education, rehabilitation, and skills training. NIH: National Institute of Mental Health

MalaCards based summary : Schizophrenia, also known as schizophrenia with or without an affective disorder, is related to childhood-onset schizophrenia and schizophrenia 2, and has symptoms including eeg abnormality, hallucinations and delusions. An important gene associated with Schizophrenia is RTN4R (Reticulon 4 Receptor), and among its related pathways/superpathways are Dopaminergic synapse and Neuroactive ligand-receptor interaction. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes.

OMIM : 53 Schizophrenia is a psychosis, a disorder of thought and sense of self. Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. There is no characteristic pathology, such as neurofibrillary tangles in Alzheimer disease (104300). Schizophrenia is a common disorder with a lifetime prevalence of approximately 1%. It is highly heritable but the genetics are complex. This may not be a single entity. Schizophrenia and bipolar disorder (see 125480) are generally considered to be separate entities, but patients who exhibit multiple symptoms of both disorders are often given the hybrid diagnosis schizoaffective disorder (Blacker and Tsuang, 1992). (181500)

UniProtKB/Swiss-Prot : 71 Schizophrenia: A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.

Genetics Home Reference : 24 Schizophrenia is a mental health disorder classified as a psychosis, which means that it affects a person's thinking, sense of self, and perceptions. The disorder typically appears during late adolescence or early adulthood.

Disease Ontology : 12 A psychotic disorder that is characterized by a disintegration of thought processes and of emotional responsiveness.

Wikipedia : 72 Schizophrenia is a mental disorder characterized by abnormal social behavior and failure to understand... more...

Related Diseases for Schizophrenia

Diseases in the Schizophrenia family:

Schizophrenia 1 Schizophrenia 3
Schizophrenia 4 Schizophrenia 6
Schizophrenia 5 Schizophrenia 7
Schizophrenia 8 Schizophrenia 2
Schizophrenia 9 Schizophrenia 10
Schizophrenia 11 Schizophrenia 12
Schizophrenia 14 Schizophrenia 13
Schizophrenia 15 Schizophrenia 16
Schizophrenia 18 Schizophrenia 19
Early-Onset Schizophrenia

Diseases related to Schizophrenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 426)
# Related Disease Score Top Affiliating Genes
1 childhood-onset schizophrenia 34.7 COMT DAOA
2 schizophrenia 2 34.6 DISC2 SCZD2
3 early-onset schizophrenia 34.6 COMT DRD3 HTR2A
4 schizophrenia 1 34.5 DISC1 DTNBP1 SCZD1
5 schizoaffective disorder 34.1 COMT DAOA DISC1 DRD3 DTNBP1 HTR2A
6 psychotic disorder 33.9 AKT1 CHI3L1 COMT DAO DAOA DISC1
7 bipolar disorder 33.1 COMT DAO DAOA DISC1 DRD3 DTNBP1
8 tardive dyskinesia 32.2 COMT DRD3 HTR2A
9 major depressive disorder 32.0 COMT DISC1 DRD3 HTR2A MTHFR
10 mood disorder 32.0 COMT DAOA DISC1 HTR2A
11 bipolar i disorder 32.0 COMT DAO DTNBP1 HTR2A
12 autism 31.9 COMT DISC1 DRD3 HTR2A SYN2
13 personality disorder 31.8 COMT DRD3 HTR2A
14 autism spectrum disorder 31.5 COMT DISC1 DRD3 HTR2A
15 obsessive-compulsive disorder 31.3 COMT DRD3 HTR2A
16 disease of mental health 31.1 COMT DISC1 DRD3 DTNBP1 HTR2A
17 pathological gambling 30.3 DRD3 HTR2A
18 parkinson disease, late-onset 30.2 AKT1 COMT DRD3 HTR2A
19 paranoid schizophrenia 12.5
20 schizophrenia 4 12.3
21 schizophrenia 15 12.2
22 schizophrenia 9 12.2
23 schizophrenia 18 12.2
24 schizophrenia 19 12.1
25 schizophrenia 3 12.0
26 schizophrenia 12 12.0
27 schizophrenia 5 11.9
28 schizophrenia 8 11.9
29 schizophrenia 14 11.9
30 schizophrenia 13 11.9
31 schizophrenia 6 11.9
32 schizophrenia 7 11.9
33 schizophrenia 10 11.9
34 schizophrenia 11 11.9
35 schizophrenia 16 11.9
36 chromosome 2p16.3 deletion syndrome 11.8
37 schizophreniform disorder 11.4
38 neuroleptic malignant syndrome 11.2
39 systemic lupus erythematosus 11.1
40 migraine with or without aura 1 11.0 COMT DRD3 HTR2A MTHFR
41 darier-white disease 10.8
42 dopamine beta-hydroxylase deficiency, congenital 10.8
43 hyperprolinemia, type i 10.8
44 chromosome 15q13.3 deletion syndrome 10.8
45 chromosome 1q21.1 deletion syndrome, 1.35-mb 10.8
46 social emotional agnosia 10.8
47 landau-kleffner syndrome 10.8
48 lupus - neurological sequelae 10.8
49 syngap1-related non-syndromic intellectual disability 10.8
50 polysubstance abuse 10.8 COMT DRD3

Comorbidity relations with Schizophrenia via Phenotypic Disease Network (PDN): (show all 16)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Bipolar Disorder
Decubitus Ulcer Deficiency Anemia
Heart Disease Hypothyroidism
Iron Deficiency Anemia Major Depressive Disorder
Paranoid Schizophrenia Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Tardive Dyskinesia

Graphical network of the top 20 diseases related to Schizophrenia:



Diseases related to Schizophrenia

Symptoms & Phenotypes for Schizophrenia

Symptoms via clinical synopsis from OMIM:

53
Neurologic Central Nervous System:
hallucinations
schizophrenia
delusions
social and occupational deterioration
disorganized speech
more
Laboratory Abnormalities:
abnormal eeg in 25% hospitalized patients


Clinical features from OMIM:

181500

Human phenotypes related to Schizophrenia:

31
# Description HPO Frequency HPO Source Accession
1 eeg abnormality 31 very rare (1%) HP:0002353
2 hallucinations 31 HP:0000738
3 schizophrenia 31 HP:0100753
4 delusions 31 HP:0000746
5 social and occupational deterioration 31 HP:0007086

UMLS symptoms related to Schizophrenia:


pseudobulbar behavioral symptoms, restlessness, personality changes, photophobia, sleep disturbances

Drugs & Therapeutics for Schizophrenia

Drugs for Schizophrenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 700)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
4
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
5
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Phase 1 146939-27-7 60854
6
Curcumin Approved, Investigational Phase 4,Phase 1,Phase 2 458-37-7 969516
7
Donepezil Approved Phase 4,Phase 3,Phase 2 120014-06-4 3152
8
Clozapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 5786-21-0 2818
9
Etomidate Approved Phase 4 33125-97-2 667484 36339
10
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
11
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
12
Reboxetine Approved, Investigational Phase 4,Phase 3,Phase 1 71620-89-8, 98769-81-4 65856 123628
13
Sulpiride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 15676-16-1 5355
14
Metformin Approved Phase 4,Phase 3 657-24-9 4091 14219
15
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
16
Huperzine A Approved, Investigational Phase 4,Phase 2 102518-79-6
17
Haloperidol Approved Phase 4,Phase 3,Phase 2,Phase 1 52-86-8 3559
18
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 112111-43-0
19
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 68693-11-8 4236
20
Guanfacine Approved, Investigational Phase 4,Phase 2 29110-47-2 3519
21
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 10118-90-8 5281021
22
Chlorpromazine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-53-3 2726
23
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
24 Benperidol Approved, Investigational Phase 4,Phase 3,Phase 2 2062-84-2
25 bromperidol Approved, Investigational Phase 4,Phase 3 10457-90-6
26
Fluphenazine Approved Phase 4,Phase 3,Phase 2 69-23-8 3372
27
Fluspirilene Approved, Investigational Phase 4,Phase 3 1841-19-6 3396
28 Perazine Approved, Investigational Phase 4,Phase 3 84-97-9
29
Perphenazine Approved Phase 4,Phase 3,Phase 2 58-39-9 4748
30
Pimozide Approved Phase 4,Phase 3,Phase 2 2062-78-4 16362
31
Asenapine Approved Phase 4,Phase 3,Phase 2,Phase 1 85650-56-2, 65576-45-6 3001386
32
Methyltestosterone Approved Phase 4 58-18-4 6010
33
Testosterone Approved, Investigational Phase 4 58-22-0 6013
34
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
35
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
36
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 51-45-6, 75614-87-8 774
37
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
38
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 50-56-6 53477758 439302
39
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19982-08-2 4054
40
Fluvoxamine Approved, Investigational Phase 4,Phase 3 54739-18-3 5324346 3404
41
Zinc Approved, Investigational Phase 4,Phase 1 7440-66-6 32051 23994
42
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
43
Famotidine Approved Phase 4,Phase 2,Phase 3 76824-35-6 3325
44
Galantamine Approved Phase 4,Phase 2,Phase 3 357-70-0 9651
45
Trifluoperazine Approved, Investigational Phase 4,Phase 3 117-89-5 5566
46
Menthol Approved Phase 4 2216-51-5 16666
47
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 1 50-36-2 446220 5760
48
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 1 61869-08-7 43815
49
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 20748-11-2, 113-45-1 4158
50
Methotrimeprazine Approved, Investigational Phase 4,Phase 3,Phase 2 60-99-1 72287

Interventional clinical trials:

(show top 50) (show all 3045)

# Name Status NCT ID Phase Drugs
1 Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia Unknown status NCT02040883 Phase 4 Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole;Tandospirone
2 Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients Unknown status NCT02298985 Phase 4 Curcumin;placebo
3 Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia Unknown status NCT02210962 Phase 4
4 Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients Unknown status NCT01399450 Phase 4 paliperidone
5 A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia Unknown status NCT01490567 Phase 4 Donepezil;placebo
6 Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia Unknown status NCT02049021 Phase 4
7 Magnetic Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia Unknown status NCT00186771 Phase 4
8 Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia Unknown status NCT02282085 Phase 4 Aripiprazole Once-Monthly;Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
9 The New Strategy for Pharmacological Treatment in People With Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
10 Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia Unknown status NCT01300364 Phase 4 Reboxetine;citalopram (SSRI)
11 Association of Amisulpride Response in Schizophrenia With Brain Image Unknown status NCT02095938 Phase 4 amisulpride
12 Diabetes Prevention Program in Schizophrenia [DPPS] Unknown status NCT00182494 Phase 4
13 Alleviating the Metabolic Side Effects of Antipsychotic Medications Unknown status NCT01567124 Phase 4 Moxonidine;Placebo;Moxonidine;Placebo
14 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4 long-acting injectable risperidone;long acting injectable risperidone;long acting injectable risperidone
15 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
16 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4 aripiprazole
17 Antipsychotic Effects on Brain Function in Schizophrenia Unknown status NCT01913327 Phase 4 Aripiprazole;Risperidone;Modafinil
18 Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH) Unknown status NCT01822418 Phase 4 agomelatine
19 Identification and Treatment of the Liability to Develop Schizophrenia Unknown status NCT00305474 Phase 4 Risperidone
20 Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
21 PREvent First Episode Relapse (PREFER) Unknown status NCT00220714 Phase 4 atypical antipsychotics:oral vs. long-acting route
22 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
23 Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study Unknown status NCT01133080 Phase 4 Minocycline;placebo
24 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4 Quetiapine fumarate;Haloperidol
25 Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
26 Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch Unknown status NCT02697045 Phase 4 Aripiprazole 400mg LAI
27 Optimization of Acute Treatment in First Episode Schizophrenia Unknown status NCT00157378 Phase 4 Risperidone, Haloperidol
28 Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype Unknown status NCT01078870 Phase 4 Lexapro;Cymbalta;Placebo
29 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
30 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
31 Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning Unknown status NCT00937261 Phase 4 Risperidone;Paliperidone
32 A Pharmacokinetic Study of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
33 Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4 Quetiapine(Seroquel-XR) 50~800mg a day
34 Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients Unknown status NCT02307396 Phase 4 Olanzapine;Amisulpride;Risperidone;Haloperidol;Quetiapine;Perphenazine;Sulpiride;bromperidol;Zuclopenthixol;Thioridazine;Paliperidone;Ziprasidone;Benperidol;Fluspirilene;Pimozide;Perazine;Fluphenazine;Flupentixole;Sertindole
35 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
36 The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine Unknown status NCT01654640 Phase 4 Metformin;Placebo (for metformin)
37 Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4 Aripiprazole; Quetiapine
38 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
39 Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4 Quetiapine XR
40 Investigator Initiated Study - Asenapine Early Psychosis Unknown status NCT01968161 Phase 4 Asenapine
41 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
42 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
43 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
44 Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
45 Estrogen and Perimenopausal Depression Unknown status NCT00229450 Phase 4 estrogen
46 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4 Aripiprazole;Quetiapine
47 Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features Unknown status NCT00202293 Phase 4 Olanzapine;Lithium;Chlorpromazine
48 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4 Lamotrigine;Placebo
49 A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With Antipsychotics Completed NCT02712463 Phase 4
50 Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate Completed NCT02532842 Phase 4

Search NIH Clinical Center for Schizophrenia

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: schizophrenia

Genetic Tests for Schizophrenia

Genetic tests related to Schizophrenia:

# Genetic test Affiliating Genes
1 Schizophrenia 28 AKT1 APOL2 APOL4 CHI3L1 COMT DAO DAOA DISC1 DISC2 DRD3 DTNBP1 HTR2A MTHFR RTN4R SYN2

Anatomical Context for Schizophrenia

MalaCards organs/tissues related to Schizophrenia:

38
Brain, Cortex, Testes, Prefrontal Cortex, Eye, Cingulate Cortex, Heart

Publications for Schizophrenia

Articles related to Schizophrenia:

(show top 50) (show all 7194)
# Title Authors Year
1
Correction: Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study. ( 29451914 )
2018
2
Association between variations in the disrupted in schizophrenia 1 gene and schizophrenia: A meta-analysis. ( 29410289 )
2018
3
Psychotic Symptoms and Attitudes toward Medication Mediate the Effect of Insight on Personal-Social Functions in Patients with Schizophrenia: One-Year Randomized Controlled Trial and Follow-Up. ( 29444522 )
2018
4
Effects of Environmental Enrichment on Nicotine Sensitization in Rats Neonatally Treated with Quinpirole: Analyses of Glial Cell Line-Derived Neurotrophic Factor and Implications towards Schizophrenia. ( 29444518 )
2018
5
C4A mRNA expression in PBMCs predicts the presence and severity of delusions in schizophrenia and bipolar disorder with psychosis. ( 29449061 )
2018
6
Analyzing the genes related to nicotine addiction or schizophrenia via a pathway and network based approach. ( 29440730 )
2018
7
Obsessions in Schizophrenia: A need for reconsideration? ( 29438921 )
2018
8
DNA methylation analyses of the candidate genes identified by a methylome-wide association study revealed common epigenetic alterations in schizophrenia and bipolar disorder. ( 29430824 )
2018
9
Psychosocial functioning in patients with psychotic and non-psychotic bipolar I disorder. A comparative study with individuals with schizophrenia. ( 29316520 )
2018
10
Case of myxedema coma induced by lithium carbonate in a patient with schizophrenia. ( 29232051 )
2018
11
Altered corticostriatal pathway in first-episode paranoid schizophrenia: Resting-state functional and causal connectivity analyses. ( 29122402 )
2018
12
The phosphodiesterase 2A inhibitor TAK-915 ameliorates cognitive impairments and social withdrawal in N-methyl-D-aspartate receptor antagonist-induced rat models of schizophrenia. ( 29440309 )
2018
13
The Impact of Sex Differences on Odor Identification and Facial Affect Recognition in Patients with Schizophrenia Spectrum Disorders. ( 29445345 )
2018
14
Zotepine-induced convulsion at a low dose in a case of paranoid schizophrenia. ( 29363876 )
2018
15
Altered Functional Connectivity of the Default Mode Network in Patients With Schizo-obsessive Comorbidity: A Comparison Between Schizophrenia and Obsessive-compulsive Disorder. ( 29365198 )
2018
16
Modification of the association between antipsychotic treatment response and childhood adversity by MMP9 gene variants in a first-episode schizophrenia cohort. ( 29448178 )
2018
17
The Glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder. ( 29125018 )
2018
18
Resting-state thalamic dysconnectivity in schizophrenia and relationships with symptoms. ( 29444726 )
2018
19
Genetic risk between the CACNA1I gene and schizophrenia in Chinese Uygur population. ( 28725167 )
2018
20
A comprehensive review of the genetic and biological evidence supports a role for MicroRNA-137 in the etiology of schizophrenia. ( 29442441 )
2018
21
Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis. ( 29439067 )
2018
22
Is it Possible for Late Onset Schizophrenia to Masquerade as Manganese Psychosis? ( 29438152 )
2018
23
Validation study of the early onset schizophrenia diagnosis in the Danish Psychiatric Central Research Register. ( 29299680 )
2018
24
Differential neural reward mechanisms in treatment-responsive and treatment-resistant schizophrenia. ( 29439750 )
2018
25
Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study. ( 29392373 )
2018
26
Biophysical insights from a single chain camelid antibody directed against the Disrupted-in-Schizophrenia 1 protein. ( 29324815 )
2018
27
Adrenal myelolipoma with hyperandrogenemia and schizophrenia. ( 29440927 )
2018
28
Haplotype Association of the<i>MAP2K5</i>Gene with Antipsychotics-Induced Symptoms of Restless Legs Syndrome among Patients with Schizophrenia. ( 29422930 )
2018
29
The interaction of NOS1AP, DISC1, DAOA, and GSK3B confers susceptibility of early-onset schizophrenia in Chinese Han population. ( 29100974 )
2018
30
Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia: A Network Analysis. ( 29450447 )
2018
31
Psychological Distress Among Caregivers of Individuals With a Diagnosis of Schizophrenia or Schizoaffective Disorder. ( 28967321 )
2018
32
Association study of BDNF and DRD3 genes with alcohol use disorder in Schizophrenia. ( 29357295 )
2018
33
Tobacco smoking is associated with antipsychotic medication, physical aggressiveness, and alcohol use disorder in schizophrenia: results from the FACE-SZ national cohort. ( 29396753 )
2018
34
Differences in frontotemporal dysfunction during social and non-social cognition tasks between patients with autism spectrum disorder and schizophrenia. ( 29445197 )
2018
35
The aprosody of schizophrenia: Computationally derived acoustic phonetic underpinnings of monotone speech. ( 29449060 )
2018
36
Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia. ( 29449054 )
2018
37
Are negative symptoms in schizophrenia a distinct therapeutic target? ( 29440953 )
2018
38
Childhood trauma in schizophrenia spectrum disorders as compared to substance abuse disorders. ( 29360053 )
2018
39
The impact of Disrupted-in-Schizophrenia 1 (DISC1) on the dopaminergic system: a systematic review. ( 28140405 )
2017
40
Common variants on 2p16.1, 6p22.1 and 10q24.32 are associated with schizophrenia in Han Chinese population. ( 27922604 )
2017
41
Genetic risk for schizophrenia and psychosis in Alzheimer disease. ( 28461698 )
2017
42
Examining methods, messengers and behavioural theories to disseminate physical activity information to individuals with a diagnosis of schizophrenia: a scoping review. ( 28084841 )
2017
43
Association of Polymorphisms of the Receptor for Advanced Glycation Endproducts Gene with Schizophrenia in a Han Chinese Population. ( 28373983 )
2017
44
Using First Rank Symptoms to Assess for Schizophrenia. ( 28945491 )
2017
45
A Computational Approach to Identify the Biophysical and Structural Aspects of Methylenetetrahydrofolate Reductase (MTHFR) Mutations (A222V, E429A, and R594Q) Leading to Schizophrenia. ( 28427558 )
2017
46
Association between NAT2 polymorphisms and the risk of schizophrenia in a Northern Chinese Han population. ( 28187106 )
2017
47
Day/night changes in serum S100B protein concentrations in acute paranoid schizophrenia. ( 28188811 )
2017
48
Association of I^-Secretase Functional Polymorphism with Risk of Schizophrenia. ( 28384043 )
2017
49
Identification of Genetic Loci Jointly Influencing Schizophrenia Risk and the Cognitive Traits of Verbal-Numerical Reasoning, Reaction Time, and General Cognitive Function. ( 28746715 )
2017
50
Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. ( 28086761 )
2017

Variations for Schizophrenia

UniProtKB/Swiss-Prot genetic disease variations for Schizophrenia:

71
# Symbol AA change Variation ID SNP ID
1 RTN4R p.Arg119Trp VAR_079154 rs74315508
2 RTN4R p.Arg196His VAR_079155 rs74315509
3 RTN4R p.Arg292His VAR_079231
4 RTN4R p.Arg377Gln VAR_079235 rs779384862
5 RTN4R p.Arg377Trp VAR_079236 rs748655075

ClinVar genetic disease variations for Schizophrenia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SETD1A NM_014712.2(SETD1A): c.518-2A> G single nucleotide variant Pathogenic rs869312829 GRCh37 Chromosome 16, 30974752: 30974752
2 SETD1A NM_014712.2(SETD1A): c.1272delC (p.Tyr425Thrfs) deletion Pathogenic rs869312830 GRCh37 Chromosome 16, 30976335: 30976335
3 SETD1A NM_014712.2(SETD1A): c.1938C> G (p.Tyr646Ter) single nucleotide variant Pathogenic rs770913157 GRCh37 Chromosome 16, 30977140: 30977140
4 SETD1A NM_014712.2(SETD1A): c.2171dupC (p.Ala725Serfs) duplication Pathogenic rs869312832 GRCh38 Chromosome 16, 30966052: 30966052
5 SETD1A NM_014712.2(SETD1A): c.2209C> T (p.Gln737Ter) single nucleotide variant Pathogenic rs869312831 GRCh37 Chromosome 16, 30977411: 30977411

Copy number variations for Schizophrenia from CNVD:

7 (show top 50) (show all 5299)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13368 1 1 16700000 Deletion Schizophrenia
2 13397 1 1 2300000 Gain OR4F16 Schizophrenia
3 13398 1 1 2300000 Gain OR4F29 Schizophrenia
4 13399 1 1 2300000 Gain OR4F3 Schizophrenia
5 13400 1 1 2300000 Gain OR4F5 Schizophrenia
6 13737 1 1 247249719 Deletion Schizophrenia
7 13808 1 1 6300000 Copy number Schizophrenia
8 13997 1 102428272 102625426 Deletion Schizophrenia
9 14001 1 102628520 102630703 Deletion Schizophrenia
10 14084 1 103900163 104069733 Duplication Schizophrenia
11 14085 1 103904299 104069733 Duplication Schizophrenia
12 14102 1 103957313 104069733 Deletion Schizophrenia
13 14103 1 103957313 104069733